EMA
Abbvie and Biogen pull MS drug Zinbryta following urgent EMA safety review
March 5, 2018Sales and Marketing AQbbvie, Biogen, EMA, Europe, mulyiple sclerosis, pharma, zinbryta
Biogen and Abbvie have announced their intention to voluntarily withdraw their multiple sclerosis therapy Zinbryta (daclizumab) from all global markets …
Top Ten most popular articles on Pharmafile.com this week
March 2, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Alzheimer's, AstraZeneca, Botox, Celgene, EMA, FDA, Merck, Mylan, Pfizer, Roche, Takeda, ipsen, vaccines
We’re already into March and, trying to put a bad start to the year behind them on Alzheimer’s research, the …
EMA set to also revise guidelines of Alzheimer’s trials
February 28, 2018Medical Communications Alzheimer's, EMA, FDA, biotech, drugs, pharma, pharmaceutical
The EMA, following on from the FDA’s lead earlier this month, has announced that it will revise its guidelines on …
Novo’s Ozempic secures European approval in type 2 diabetes
February 12, 2018Sales and Marketing EC, EMA, Europe, Novo Nordisk, diabetes, pharma
Novo Nordisk has revealed that its drug Ozempic (semaglutide) has received approval from the European Commission (EC) as a monotherapy …
New Year, new goals
February 8, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CRUK, Cancer Research UK, Chiesi, EMA, FDA, Genetic Alliance, pharma
With the New Year begun in earnest, Pharmafocus speaks to a range of players in pharma and the life sciences …
Top Ten most popular articles on Pharmafile.com this week
February 2, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ablynx, Alzheimer's, Apotex, AstraZeneca, Brexit Health Alliance, CDC, Duchenne Muscular Dystrophy, EMA, Italy, Sanofi, amazon, brexit, santhera, top ten
It’s the first Friday of February, and it’s time for another recap of the top ten articles most popular with …
Italy refuses to give up hope on EMA HQ
January 30, 2018Medical Communications, Research and Development EMA, amsterdam, biotech, drugs, pharma, pharmaceutical
It is no secret that Milan was not best pleased that it was pipped to the post to host the …
Santhera’s Raxone rejected in Europe for Duchenne muscular dystrophy
January 29, 2018Sales and Marketing Duchenne Muscular Dystrophy, EMA, Europe Santhera, pharma
While the EMA’s Committee for Medicinal products for Human Use (CHMP) recommended a spree of treatments over the past week, …
Novartis’ CAR T therapy Kymriah scores accelerated approval in both Europe and US
January 17, 2018Research and Development, Sales and Marketing CAR T, CAR-T, EMA, Europe, FDA, Kymriah, Novartis, US, pharma
Following up last year’s ground-breaking news that CAR T therapy Kymriah had become the first such treatment to be approved …
Pharmafile.com’s top ten stories of 2017
December 22, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abbott, Actelion, Amgen, AstraZeneca, Cyber attack, EMA, European Commission, Humira, J&J, JJ, Johnson & Johnson, MSD, Sanofi, Shire, Teva, biosimilar, brexit
After a packed year that has flown by, we’ve reached the final top ten of 2017. Below you can find …
Samsung Bioepis’ Ontruzant becomes first Herceptin biosimilar approved in Europe
November 20, 2017Sales and Marketing EMA, Herceptin, Roche, Samsung Bioepis
Samsung Bioepis has announced that Ontruzant, the company’s biosimilar version of Roche’s Herceptin, has been awarded marketing authorisation in Europe …
EMA Headquarters: There’s no place like home
November 13, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMA, biotech, brexit, drugs, pharma, pharmaceutical
With the result of the Brexit referendum, the future of the EMA’s London headquarters was cast in doubt. Now, 19 …
MSD withdraws European application of Keytruda combo in lung cancer
October 30, 2017Sales and Marketing EMA, MSD, keytruda
MSD has been forced to withdraw its EU marketing application for Keytruda (pembrolizumab) in combination with pemetrexed and carboplatin as …
The November 2017 issue of Pharmafocus is now live!
October 23, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CAR-T, EMA, NHS, Pharmafocus, Trump, brexit, clinical trial transparency, pharma
The November edition of Pharmafocus is now live and available to read online here!
EMA responds to criticism of its cancer drug approvals
October 17, 2017Manufacturing and Production, Medical Communications Cancer, EMA, biotech, drugs, oncology, pharma, pharmaceutical
The EMA received a broadside just less than two week ago from a group of researchers that had studied data …
Latest content
Five Facts about cardiovascular disease
